Journal of Hepatology
Volume 52, Issue 1 , Pages 25-31 , January 2010

Shortened treatment duration in treatment-naive genotype 1 HCV patients with rapid virological response: A meta-analysis

  • Christophe Moreno

      Affiliations

    • Department of Gastroenterology and Hepatopancreatology, Hôpital Erasme, Université Libre de Bruxelles, Bruxelles, Belgium
    • The first and second author contributed equally to this publication.
    • ,
  • Pierre Deltenre

      Affiliations

    • Service d’Hepatologie, Hôpital Claude Huriez, Lille, France
    • Service d’Hépato-Gastroentérologie, Hôpital de Jolimont, Haine-Saint-Paul, Belgium
    • The first and second author contributed equally to this publication.
    • ,
  • Jean-Michel Pawlotsky

      Affiliations

    • National Reference Centre for Viral Hepatitis B, C and delta, Department of Virology & INSERM U955, Hôpital Henri Mondor, 94010 Créteil, France
    • ,
  • Jean Henrion

      Affiliations

    • Service d’Hépato-Gastroentérologie, Hôpital de Jolimont, Haine-Saint-Paul, Belgium
    • ,
  • Michael Adler

      Affiliations

    • Department of Gastroenterology and Hepatopancreatology, Hôpital Erasme, Université Libre de Bruxelles, Bruxelles, Belgium
    • ,
  • Philippe Mathurin

      Affiliations

    • Service d’Hepatologie, Hôpital Claude Huriez, Lille, France
    • INSERM U795, Lille, France
    • Corresponding Author InformationCorresponding author. Address: Service d’Hépatogastroentérologie, Hôpital Claude Huriez 1er étage Aile Est, Avenue Michel Polonovoski, CHRU Lille 59037, France. Tel.: +33 3 20 44 55 97; fax: +33 3 20 44 55 64.

Received 7 May 2009 ,Revised 13 July 2009 ,Accepted 3 August 2009.

References 

  1. Strader DB, Wright T, Thomas DL, Seeff LB. Diagnosis, management, and treatment of hepatitis C. Hepatology. 2004;39:1147–1171
  2. Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Gonçales FL, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med. 2002;347:975–982
  3. Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet. 2001;358:958–965
  4. Davis GL, Wong JB, McHutchison JG, Manns MP, Harvey J, Albrecht J. Early virologic response to treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C. Hepatology. 2003;38:645–652
  5. Ferenci P, Fried MW, Shiffman ML, Smith CI, Marinos G, Goncales FL, et al. Predicting sustained virological responses in chronic hepatitis C patients treated with peginterferon alfa-2a (40 KD)/ribavirin. J Hepatol. 2005;43:425–433
  6. Jensen DM, Morgan TR, Marcellin P, Pockros PJ, Reddy KR, Hadziyannis SJ, et al. Early identification of HCV genotype 1 patients responding to 24 weeks peginterferon alpha-2a (40 kd)/ribavirin therapy. Hepatology. 2006;43:954–960
  7. Liu CH, Liu CJ, Lin CL, Liang CC, Hsu SJ, Yang SS, et al. Pegylated interferon-alpha-2a plus ribavirin for treatment-naive Asian patients with hepatitis C virus genotype 1 infection: a multicenter, randomized controlled trial. Clin Infect Dis. 2008;47:1260–1269
  8. Mangia A, Minerva N, Bacca D, Cozzolongo R, Ricci GL, Carretta V, et al. Individualized treatment duration for hepatitis C genotype 1 patients: a randomized controlled trial. Hepatology. 2008;47:43–50
  9. Yu ML, Dai CY, Huang JF, Chiu CF, Yang YH, Hou NJ, et al. Rapid virological response and treatment duration for chronic hepatitis C genotype 1 patients: a randomized trial. Hepatology. 2008;47:1884–1893
  10. Zeuzem S, Buti M, Ferenci P, Sperl J, Horsmans Y, Cianciara J, et al. Efficacy of 24 weeks treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C infected with genotype 1 and low pretreatment viremia. J Hepatol. 2006;44:97–103
  11. Pegasys product label, Roche 2005. Available at: http://www.rocheusa.com/products/pegasys/pi.pdf.
  12. PEG-Intron product label, Schering-Plough 2005. Available at: http://www.spfiles.com/pipeg-intron.pdf.
  13. Sacks HS, Berrier J, Reitman D, Angoma-Berk VA, Chalmers TC. Meta-analysis of randomized controlled trials. N Engl J Med. 1987;19:450–455
  14. Poynard T, Conn HO. The retrieval of randomized clinical trials in liver disease from the medical literature. A comparison of MEDLARS and manual methods. Control Clin Trials. 1985;6:271–279
  15. Demets DL. Methods for combining randomized clinical trials: strengths and limitations. Stat Med. 1987;6:341–350
  16. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7:177–188
  17. Cochran W. The combination of estimates from different experiments. Biometrics. 1954;10:101–129
  18. Arase Y, Suzuki F, Sezaki H, Suzuki Y, Kawamura Y, Kobayashi M, et al. Suitable treatment period in patients with virological response during combination therapy of peginterferon and ribavirin for chronic hepatitis C. Intern Med. 2008;47:1301–1307
  19. Sarrazin C, Schwendy S, Moller B, Dikopoulos N, Buggisch P, Encke J, et al. Individualized treatment duration with peginterferon-alfa-2b and ribavirin for 24, 30 or 36 weeks in HCV genotype 1-infected patients with undetectable HCV-RNA early during therapy (indiv-2 study). J Hepatol. 2009;50(Suppl. 1):S236
  20. Ferenci P, Laferl H, Scherzer TM, Gschwantler M, Maieron A, Brunner H, et al. Peginterferon alfa-2a and ribavirin for 24 weeks in hepatitis C type 1 and 4 patients with rapid virological response. Gastroenterology. 2008;135:451–458
  21. Tang KH, Herrmann E, Pachiadakis I, Paulon E, Tatman N, Zeuzem S, et al. Clinical trial: individualized treatment duration for hepatitis C virus genotype 1 with peginterferon-alpha 2a plus ribavirin. Aliment Pharmacol Ther. 2008;27:810–819
  22. Bellobuono A, Mondazzi L, Tempini S, Chiodo F, Magliano E, Mondini C, et al. Should patients with early loss of serum HCV-RNA during alpha interferon therapy for chronic hepatitis C be treated for 6 or 12 months?. J Hepatol. 1999;30:8–13
  23. Berg T, Weich V, Teubel G, Klinker H, Rasenack J, Hinrichsen H, et al. Individualized treatment strategy with peginterferon alpha-2b (peg-IFN alfa) plus ribavirin according to early viral kinetics in hepatitis C virus (HCV) type 1 infected patients. J Hepatol. 2006;44(S2):A559
  24. Liu CH, Liu CJ, Lin CL, Liang CC, Hsu SJ, Yang SS, et al. A randomized trial of 24- versus 48-week peginterferon alfa-2a plus ribavirin for treatment-naïve Taiwanese patients with hepatitis C virus genotype 1 infection. Hepatology. 2008;48(S):A26
  25. Mangia A, Minerva N, Carretta V, Bacca D, Cozzolongo R, Vuturo O, et al. Predictors of rapid virologic response (RVR) in HCV genotype 1 chronic infected pts: results of a randomized controlled trial on individualized treatment. 2006;44:A1124
  26. Yu ML, Dai CY, Huang JF, Lee LP, Hsieh MY, Chiu CF, et al. High prevalence of cure in HCV genotype 1 patients with a low viral load achieving an RVR treated for 24 weeks with Peginterferon alfa-2a (Pegasys®) plus Ribavirin (Copegus®): prospective, randomized, controlled study comparing 24 and 48 weeks of treatment. Hepatology. 2007;A1316
  27. Berg T, Weich V, Teuber G, Klinker H, Möller B, Rasenack J, et al. Evaluation of the efficacy of an 18 week short treatment duration in HCV type 1 infected patients based upon early viral kinetics: an approach to recognise «super-responders». Hepatology. 2006;44:A346
  28. Brandao C, Barone A, Carrilho F, Silva A, Patelli M, Caramori C, et al. The results of a randomized trial looking at 24 weeks vs 48 weeks of treatment with peginterferon alpha-2a (40 kDa) and ribavirin combination therapy in patients with chronic hepatitis C genotype 1. J Viral Hepat. 2006;13:552–559
  29. Zeuzem S, Pawlotsky JM, Lukasiewicz E, von Wagner M, Goulis I, Lurie Y, et al. International, multicenter, randomized, controlled study comparing dynamically individualized versus standard treatment in patients with chronic hepatitis C. J Hepatol. 2005;43:250–257
  30. Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med. 2002;21:1539–1558
  31. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315:629–634
  32. Sarrazin C, Shiffman M, Hadziyannis S, Lin A, Colucci G, Ishida H, et al. What is the impact of higher sensitivity assay on response-guided therapy in hepatitis C virus (HCV)? Comparative analysis between Taqman and Amplicor tests from two large randomized international trials of Pegasys plus Copegus. Hepatology. 2007;46:813A
  33. Hadziyannis SJ, Sette HJ, Morgan TR, Balan V, Diago M, Marcellin P, et al. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med. 2004;140:346–355
  34. Romero-Gomez M, Del Mar Viloria M, Andrade RJ, Salmeron J, Diago M, Fernandez-Rodriguez CM, et al. Insulin resistance impairs sustained response rate to peginterferon plus ribavirin in chronic hepatitis C patients. Gastroenterology. 2005;128:636–641
  35. Charlton MR, Pockros PJ, Harrison SA. Impact of obesity on treatment of chronic hepatitis C. Hepatology. 2006;43:1177–1186
  36. Roffi L, Colloredo G, Pioltelli P, Bellati G, Pozzpi M, Parravicini P, et al. Pegylated interferon-alpha2b plus ribavirin: an efficacious and well-tolerated treatment regimen for patients with hepatitis C virus related histologically proven cirrhosis. Antivir Ther. 2008;13:663–673

PII: S0168-8278(09)00649-7

doi: 10.1016/j.jhep.2009.10.003

Journal of Hepatology
Volume 52, Issue 1 , Pages 25-31 , January 2010

Article Tools

* Image Usage & Resolution